Page 114 - 南京医科大学自然版
P. 114
第44卷第5期
·702 · 南 京 医 科 大 学 学 报 2024年5月
能够结合TREM2并激活下游信号通路,调控小胶质 zheimer’s disease patients[J]. Mol Brain,2022,15(1):
细胞吞噬及增殖功能 [82-83] 。Ⅰ期临床试验表明其具 83
有良好的安全性及耐受性。而针对脑脊液中可溶 [7] BELLENGUEZ C,KÜÇÜKALI F,JANSEN I E,et al. New
insights into the genetic etiology of Alzheimer’s disease
性集落刺激因子1受体和sTREM2 两种生物标志物
and related dementias[J]. Nat Genet,2022,54(4):412-
的持续追踪初步提示了 AL002 的有效性 [84] 。目前
436
进行的Ⅱ期临床试验将进一步验证其治疗 AD 患
[8] REZAZADEH M,HOSSEINZADEH H,MORADI M,et al.
者的疗效及安全性。VG⁃3927 是由 Vigil 公司研发 Genetic discoveries and advances in late⁃onset Alzheimer’s
的用于治疗 AD 的小分子 TREM2 激动剂。该药能 disease[J]. J Cell Physiol,2019,234(10):16873-16884
够透过血⁃脑屏障,高效激活 TREM2 下游信号通 [9] JONAS L A,JAIN T,LI Y M. Functional insight into
路,调控小胶质细胞激活状态及功能。目前进行 LOAD ⁃ associated microglial response genes[J]. Open
的Ⅰ期临床试验正在验证其治疗AD患者的安全性 Biol,2022,12(1):210280
[85]
及耐受性 。 [10]LI R,WANG X,HE P F. The most prevalent rare coding
variants of TREM2 conferring risk of Alzheimer’s dis⁃
6 总结与展望 ease:a systematic review and meta⁃analysis[J]. Exp Ther
Med,2021,21(4):347
近年来,TREM2 在 AD 中所扮演的重要角色得 [11]JIANG T,YU J T,ZHU X C,et al. TREM2 in Alzheimer’
到了医学界的广泛关注。在遗传学方面,未来亟需 s disease[J]. Mol Neurobiol,2013,48(1):180-185
大样本WES或GWAS进一步发掘与AD发病密切相 [12]GUERREIRO R,WOJTAS A,BRAS J,et al. TREM2 vari⁃
关的 TREM2 变异位点;而已发现的 TREM2 相关变 ants in Alzheimer’s disease[J]. N Engl J Med,2013,368
异有待在不同种族及人群中进一步验证。在发病 (2):117-127
机制方面,TREM2 和 sTREM2 参与 AD 发病的生物 [13]JONSSON T,STEFANSSON H,STEINBERG S,et al.
Variant of TREM2 associated with the risk of Alzheimer’s
学机制以及TREM2变异影响AD发病风险的分子机
disease[J]. N Engl J Med,2013,368(2):107-116
制尚待更多的基础研究进一步探明。在治疗方面,期
[14]DURMANOVA V,JAVOR J,PARNICKA Z,et al. TREM2
待更多靶向TREM2的抗体及小分子药物在未来投入 coding variants in Slovak Alzheimer’s disease patients[J].
研发并获批临床使用,从而为AD患者的治疗带来新 J Integr Neurosci,2022,21(4):105
的选择。 [15]BENITEZ B A,COOPER B,PASTOR P,et al. TREM2 is
associated with the risk of Alzheimer’s disease in Spanish
[参考文献]
population[J]. Neurobiol Aging,2013,34(6):1711.e15-
[1] MONTEIRO A R,BARBOSA D J,REMIÃO F,et al. Al⁃ 1711.e17
zheimer’s disease:insights and new prospects in disease [16]YU J T,JIANG T,WANG Y L,et al. Triggering receptor
pathophysiology,biomarkers and disease ⁃ modifying expressed on myeloid cells 2 variant is rare in late⁃onset
drugs[J]. Biochem Pharmacol,2023,211:115522 Alzheimer’s disease in Han Chinese individuals[J]. Neu⁃
[2] SELF W K,HOLTZMAN D M. Emerging diagnostics and robiol Aging,2014,35(4):937
therapeutics for Alzheimer disease[J]. Nat Med,2023,29 [17]JIANG T,TAN L,CHEN Q,et al. A rare coding variant in
(9):2187-2199 TREM2 increases risk for Alzheimer’s disease in Han
[3] 张亚茹,张 一,郁金泰. 2022年阿尔茨海默病重要研 Chinese[J]. Neurobiol Aging,2016,42:217
究进展[J]. 南京医科大学学报(自然科学版),2023,43 [18]CUYVERS E,BETTENS K,PHILTJENS S,et al. Investi⁃
(4):563-568 gating the role of rare heterozygous TREM2 variants in Al⁃
[4] LENG F D,EDISON P. Neuroinflammation and microgli⁃ zheimer’s disease and frontotemporal dementia[J]. Neu⁃
al activation in Alzheimer disease:where do we go from robiol Aging,2014,35(3):726
here?[J]. Nat Rev Neurol,2021,17(3):157-172 [19]OGONOWSKI N,SANTAMARIA⁃GARCIA H,BAEZ S,
[5] NGUYEN T T,NGUYEN T T D,NGUYEN T K O,et al. et al. Frontotemporal dementia presentation in patients
Advances in developing therapeutic strategies for Al⁃ with heterozygous p.H157Y variant of TREM2[J]. J Med
zheimer’s disease[J]. Biomed Pharmacother,2021,139: Genet,2023,60(9):894-904
111623 [20]LI X T,SUN Y M,GONG L Y,et al. A novel homozygous
[6] CALDWELL A B,ANANTHARAMAN B G,RAMACH⁃ mutation in TREM2 found in a Chinese early ⁃ onset de⁃
ANDRAN S,et al. Transcriptomic profiling of sporadic Al⁃ mentia family with mild bone involvement[J]. Neurobiol